The EU marketing authorization application (MAA) for Sanofi Genzyme's olipudase alfa will be reviewed under the European Medicines Agency's accelerated assessment mechanism when the company files for approval.
Olipudase alfa is a potential therapy for the long-term treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD),...








